Six abstracts; including new phase 2 data for nemolizumab across PN and AD and new real-world evidence highlighting the PN disease burden being presented
Prurigo nodularis: Rapid onset of action with over three times greater itch reduction versus placebo within 48 hours of the first dose and a four times greater improvement in sleep versus placebo as early as Day 4
Atopic dermatitis: Improvement of the clinical signs indicated by SCORAD components apparent at week 1 and increased through week 16
LAUSANNE, Switzerland--(BUSINESS WIRE)--Galderma today announced the presentation of new phase 2 data supporting the efficacy of its investigational monoclonal antibody, nemolizumab, at the virtual 30th EADV congress, taking place between 28 September and 2 October 2021.
Results from two key trials of nemolizumab given every 4 weeks, demonstrate rapid onset of action and significant reduction in symptoms for patients with prurigo nodularis (PN) and atopic dermatitis (AD), and new real-world evidence highlight the PN disease burden.
|
|
"We are delighted to share new analyses and clinical trial data which reinforce nemolizumab’s therapeutic potential and comprehensive benefits across prurigo nodularis and atopic dermatitis. The scientific evidence for the critical role that the IL-31 pathway plays in the inflammatory process is growing and we are committed to continuing our work diligently to bring nemolizumab to patients living with these debilitating skin conditions.”
BALDO SCASSELLATI SFORZOLINI, M.D., PH.D., GLOBAL HEAD OF R&D, GALDERMA |
